



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 09 May 2023 (#16)

**Confirm your intent to apply ASAP, but not later than 60 days before the submission date.**

Tygerberg Campus: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) • Stellenbosch Campus [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za)

**To prepare an application can take 4-18 months, depending on many factors:**

1. Mechanism for which you will apply e.g. U54, R01, D43, K43
2. Requirement of preliminary data
3. Time to assemble the research team
4. Time available to work on the grant, taking into consideration other responsibilities
5. Time for internal review

**Before starting your application, attend the 1) Generic Grant Writing Workshop and then the 2) NIH Grant Writing Workshop.**

## Important Notices

**[NOT-OD-23-109](#) Updates to Funding Opportunity Terminology.** Effective immediately, NIH will use the term **notice of funding opportunity (NOFO)** to refer to formal announcements of the availability of Federal funding through a financial assistance program. Previously, such announcements were referred to as funding opportunity announcements (**FOAs**).

**[NOT-AG-23-017](#) Update to Policy and Procedures for the Reporting of Human Subjects Enrollment Data for NIA Clinical Research Trials/Studies.** The purpose of this Notice is to inform and provide additional clarification to the research community regarding the National Institute on Aging's (NIA's) policy and procedures for reporting enrollment data for clinical research trials/studies funded through an NIA funding mechanism (including grants, contracts, and cooperative agreements).

**[NOT-HL-23-070](#) National Heart, Lung, and Blood Institute (NHLBI) Supplement to the NIH Policy for Data Management and Sharing**

**[NOT-EB-23-007](#) Notice of Intent to Publish a Notice of Funding Opportunity for National Centers for Biomedical Imaging and Bioengineering (NCBIB) (P41 Clinical Trials Optional).** The purpose of this notice is to inform the research community that the National Institute of Biomedical Imaging and Bioengineering (NIBIB) intends to reissue a Notice of Funding Opportunity [PAR-20-169](#) "National Centers for Biomedical Imaging and Bioengineering (NCBIB) (P41 Clinical Trials Optional)." First Estimated Application Due Date: September 25, 2023. This Notice encourages investigators with expertise and insights into this area of Biomedical Technology to begin to consider applying for this NOFO. This NOFO encourages grant applications for NCBIB. NCBIB are national resource centers for conducting research and development on new technologies that are driven by the needs of basic, translational, and/or clinical researchers. NCBIB also make their technologies available to other investigators, train members of the research community in the use of the technologies and disseminate the technologies broadly. Direct costs (excluding equipment) are not limited and are expected to vary among applications. Typical direct costs for NCBIB range between \$600,000 and \$750,000. In addition, up to \$500,000 can be requested for special-purpose equipment for the duration of a five-year project period.

**[NOT-TR-23-015](#) Notice of Intent to Publish a Notice of Funding Opportunity (NOFO) for the Rare Diseases Clinical Research Consortia (RDCRC) for the Rare Diseases Clinical Research Network (RDCRN).** National Center for Advancing Translational Sciences (NCATS) intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications for research to advance the diagnosis, management, and treatment of rare diseases. Each Rare Diseases Clinical Research

Consortium (RDCRC) will promote highly collaborative, multi-site, patient-centric, translational, and clinical research. It is strongly encouraged that the RDCRC study outcome measures include those that address unmet clinical trial readiness needs that will move the field of research forward from its current state. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. Estimated Publication Date of Notice of Funding Opportunity: January 24, 2024. This NOFO will utilize the U54 activity code, which supports specialized centers through multi-project cooperative agreement awards to support research activities with substantial involvement from NIH program staff.

**[NOT-OD-23-111](#) Reminder – NIH Policies for NRSA Stipends, Compensation and Other Income.** The purpose of this Notice is to remind the extramural community of the policies surrounding stipends, compensation and other income for trainees and fellows supported under Ruth L. Kirschstein National Research Service Award (NRSA) grants.

In accordance with [42 CFR Part 66](#), NIH provides stipends to NRSA fellows and trainees as a subsistence allowance to help defray living expenses during the research training experience. NIH does not provide stipends as a condition of employment with either the Federal government or the sponsoring institution (See NIH Grants Policy Statement [11.2.9.2](#) and [11.3.8.2](#)). While stipends are not provided as a condition of employment, this policy is not intended to discourage or otherwise prevent recipient institutions from hiring NRSA trainees and fellows as employees or providing them with benefits consistent with what the institution provides others at similar career stages. For more information on NRSA training and fellowship programs see:

[NIHGPS Chapter 11](#) and visit <https://researchtraining.nih.gov/programs>.

**[NOT-OD-23-117](#) Findings of Research Misconduct.** Findings of research misconduct have been made against Carlo Spirli, Ph.D. (Respondent), who was an Assistant Professor of Medicine, Department of Digestive Diseases, Yale University (YU). Respondent engaged in research misconduct in research supported by U.S. Public Health Service (PHS) funds, specifically National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH), grants R01 DK079005 and P30 DK034989. The administrative actions, including debarment for a period of four (4) years, were implemented beginning on March 28, 2023. Respondent knowingly, intentionally, or recklessly falsified and/or fabricated Western blot image data for cholangiopathies in a murine model of Congenital Hepatic Fibrosis (CHF) by reusing blot images, with or without manipulating them to conceal their similarities, and falsely relabeling them as data representing different experiments or proteins and falsifying quantitative data in associated graphs purportedly derived from those images in twenty-one (21) figures included in four (4) papers, two (2) presentations, and three (3) grant applications. In the absence of reliable image and numerical data, the figures, statistical analyses, and related text also are false.

**[NOT-AR-23-018](#) Notice of NIAMS Withdrawal from [PA-20-194](#) "Parent R21 Exploratory/Developmental Grant, Clinical Trial Required"**

**[NOT-AR-23-019](#) Notice of NIAMS Withdrawal from [PA-20-195](#) "Parent R21 Exploratory/Developmental Grant, Clinical Trial Not Allowed"**

**[NOT-HG-23-036](#) Notice to Extend the Expiration Date of [PAR-20-254](#): Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)** The purpose of this notice is to extend the expiration date for [PAR-20-254](#) - Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional) by one review cycle. An additional receipt date has been added, October 19, 2023, for new applications and November 17, 2023, for renewal, resubmission and revision applications. This Notice of Funding Application now expires on November 18, 2023.

**[NOT-HG-23-037](#) Notice to Extend the Expiration Date of [PAR-20-255](#): Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional)** The purpose of this notice is to extend the expiration date for [PAR-20-255](#) - [PAR-20-255](#): Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional) by one review cycle. An additional receipt date has been added, October 19, 2023, for new applications and November 17, 2023, for resubmission and revision applications. This Notice of Funding Opportunity now expires on November 18, 2023. The changes below are in bold italics.

**[NOT-HG-23-038](#) Notice to Extend the Expiration Date of [PAR-20-257](#): Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional).** The purpose of this notice is to extend the expiration date for [PAR-20-257](#) - Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional) by one review

cycle. An additional receipt date has been added, October 19, 2023, for new applications and November 17, 2023 for resubmission and revision applications. This Notice of Funding Opportunity now expires on November 18, 2023.

**[NOT-NS-23-081](#) Notice of Change to Submission Requirements for PAR-22-184: Clinical Trial Readiness for Rare Neurological and Neuromuscular Diseases (U01 Clinical Trial Not Allowed).** The purpose of this notice is to inform applicants of a change in the submission requirements for applications requesting \$500,000 or more in direct costs in any year in response to [PAR-22-184](#). Applicants requesting \$500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application. Furthermore, the requirements in Section IV of [PAR-22-184](#) under “Appendix” have changed

## Parent Announcements

**[NOT-OD-23-105](#) Notice to Extend Parent R01/R03/R21 Parent Notices of Funding Opportunities.** Current Key Dates  
*Expiration Date: May 8, 2023* **Modified Key Dates** *Expiration Date: May 8, 2024*

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

## Notice of Special Interest (NOSI)

**[NOT-AG-23-015](#) Alzheimer’s-Focused Administrative Supplements for NIH Grants that are Not Focused on Alzheimer’s Disease.** The participating Institutes and Centers (ICs) are inviting applications to expand existing awards that are not currently focused on Alzheimer’s disease (AD) and its related dementias (ADRD) (e.g., frontotemporal dementia, Lewy body dementia, Vascular Contributions to Cognitive Impairment and Dementia (VCID), and multiple etiology dementias) to allow the research to develop such a focus. Active awards with project end dates in FY 2025 or later are eligible. The award may not be in a terminal no-cost extension or going into a no-cost extension in FY 2024. Please note that a few ICs limit no-cost extensions in the final non-competing year of an award. For that reason, it is important to contact staff at the IC supporting the award when planning the request. Awards that currently focus on research on AD/ADRD are not eligible for this program. **Application Due Date: October 2, 2023** by 5:00 PM local time of applicant organization. Requests may be for one year of support only. Individual requests can be no more than \$250,000 in direct costs exclusive of Facilities and Administrative costs on sub-contracts but cannot exceed the direct costs of the parent award and must reflect the actual needs of the proposed project. The proposed budget period must be within the project period of the parent award.

**[NOT-AG-23-008](#) Administrative Supplements for HIV/AIDS and Aging Research.** The National Institute on Aging (NIA) and NIH Office of AIDS Research (OAR) with participating NIH Institutes and Centers announce the availability of administrative supplements to support research on HIV/AIDS and aging. Eligible parent awards include existing projects funded by the participating Institutes and Centers listed with or without an existing focus on HIV/AIDS as long as other eligibility criteria are met and are within scope of the original project. Supplemental projects may involve a variety of scientific approaches and methods provided that they are focused on HIV/AIDS, can be conducted within one year of the supplement award, address previously unforeseen research opportunities, and fit within the scope of the parent grant. Within scope means that the proposed aims do not add to or expand the existing study in a manner that would be more appropriate for a competing peer-reviewed mechanism and/or revision application. **Application Due Date: May 22, 2023**, by 5:00 PM local time of applicant organization. The proposed budget period must be within the project period of the parent award. Active awards with project end dates in FY 2024 or later are eligible. The award may not be in a terminal no-cost extension or going into a no-cost extension in FY 2023. Individual requests can be no more

than \$250,000 in direct costs exclusive of Facilities and Administrative costs on sub-contracts, cannot exceed the direct costs of the parent award, and must reflect the actual needs of the proposed project.

**[NOT-AR-23-006](#) Supporting Exploratory/Developmental Research Focused on NIAMS Core Mission Areas.** The purpose of this announcement is to notify the research community that the National Institute of Arthritis and Musculoskeletal and Skin Diseases ([NIAMS](#)) is interested in receiving Exploratory/Developmental grant applications focused on NIAMS core mission areas. Awards will provide support for innovative projects that introduce novel scientific ideas, model systems, tools, agents, targets, and technologies that have the potential for significant impact, and to substantially advance research within the NIAMS mission. These studies often assess the feasibility of a novel avenue of investigation and involve considerable risk, but have the potential to bring about breakthroughs of high value to the NIAMS research community. NOSI uses the R21 mechanism, ending NIAMS's participation in the NIH-wide parent R21 notice of funding opportunity (NOFOs). NIAMS will not accept applications to the [Parent R21 Exploratory/Developmental Grant, Clinical Trial Not Allowed](#) or the [Parent R21 Exploratory/Developmental Grant, Clinical Trial Required](#) Notices of Funding Opportunities (NOFOs) after May 7, 2023 without referencing this NOSI. This notice applies to **due dates on or after June 16, 2023** and subsequent receipt dates through January 8, 2027.

**[NOT-CA-23-059](#) Administrative Supplements for the Dog Oncology Grant Supplement (DOGS) Program.** The Division of Cancer Treatment and Diagnosis (DCTD) at the National Cancer Institute (NCI) announces the Dog Oncology Grant Supplement (DOGS) program that seeks to support collaborative, multidisciplinary research in canine oncology. DOGS applications must propose a new collaborative project that intersects two or more of the following topic areas: immuno-oncology (IO), radiation treatment (RT), and imaging. The parent award must be an active grant or cooperative agreement (R01, R37, U01, P01, P30, P50, U19, U24, or U54) with an NCI primary assignment. Collaborations with foreign institutions are allowed, but investigators must provide a justification for the collaboration. Please note that some foreign collaborations will require U.S. State Department approval by the NCI, and that may delay receipt of funding. **Due date: 15 June 2023.** Supplement budget requests must reflect the actual needs of the proposed one-year project and are limited to \$475,000 total costs per project.

**[NOT-CA-23-060](#) RNA Modifications in Cancer Biology.** The National Cancer Institute intends to stimulate research on the role of RNA modifications in the area of cancer biology. Despite the recognition that RNA modifications and editing exert a substantial impact on gene expression and function, there is a lack of mechanistic insights into the dynamic regulation of RNA modifications and their de-regulation as drivers of cancer formation. A better understanding of the extent, diversity, and crosstalk between different types of RNA modification, and the elucidation of the molecular players that read and interpret the modification code are needed to reveal the mechanisms of RNA modifications that underly cancer formation and the cancer phenotype. Gaining a better understanding of the roles of RNA modifications in cancer biology requires investigations into the what, where, when, how, and why of the processes that are inducing, regulating, and responding to these modifications. The proposed studies in response to this NOSI should be designed to generate key data as the foundation for future hypothesis-driven R01-type applications. This NOSI is a reissue of [NOT-CA-22-003](#). This notice applies to due dates on or after June 13, 2023, and subsequent receipt dates through January 8, 2026.

**[NOT-DK-23-013](#) Catalytic Tool and Technology Development in Kidney, Urologic, and Hematologic Diseases (R21 Clinical Trial Not Allowed).** National Institute of Diabetes and Digestive and Kidney Diseases ([NIDDK](#)) issuing this NOSI to announce the opportunity for investigators to apply for funding for developing novel tools and technologies that enable new lines of scientific inquiry and/or treatment, prevention, or diagnosis of Polycystic Kidney Disease (PKD). Despite advances in the understanding of the genetics of PKD, effective treatments are still lacking. Many aspects of PKD pathophysiology are poorly understood and their relationship to disease progression remains unclear. Since new discoveries are frequently catalyzed by technological innovations, developing novel tools or technologies to study PKD is essential to closing knowledge gaps and improving outcomes for people with PKD. The projects supported by this NOSI could involve proof-of-concept studies, prototyping, beta-testing, or optimization and standardization of technical specifications for subsequent deployment of the tool or technology in laboratory or clinical settings. Extensive preliminary data demonstrating feasibility and utility in PKD is an indication that the project is beyond the scope of this NOSI. This notice applies to **due dates on or after May 16, 2023 and subsequent receipt dates through November 17, 2023.**



## Notice of Funding Opportunity (NOFO)

### 1. Translating Socioenvironmental Influences on Neurocognitive Development and Addiction Risk (TransSINDA) (R34 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-DA-24-019](#)

**Type:** R34

**Application Due Date:** November 09, 2023. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Announcement:** The goal of this Notice of Funding Opportunity (NOFO) is to seek applications proposing a set of planning activities that will lay the groundwork for scientific projects aimed at using animal models and longitudinal research designs to elucidate mechanisms mediating the impact of the early-life social environment on neurobehavioral development and the risk for substance use disorders (SUD) and their comorbidities in adolescence and adulthood. This funding opportunity will support projects of limited scope focused on coordination of a multidisciplinary research team; development of the research framework, design, and approach; and activities that will establish feasibility, validity, and/or other technically qualifying results that, if successful, would support a competitive application for a larger-scale, definitive research project (e.g., R01).

**Budget:** NIDA intends to commit \$ 2.5M in FY 2024 to fund up to 8 awards. The combined budget for direct costs for the two-year project period may not exceed \$450,000. No more than \$225,000 may be requested in any single year. Application budgets should reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 2 years.

### 2. Tobacco Regulatory Science (R01 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-OD-23-017](#)

**Type:** R01

**Application Due Date:** October 06, 2023; May 06, 2024; October 04, 2024; May 02, 2025. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Announcement:** The purpose of this Notice of Funding Opportunity (NOFO) is to invite R01 applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health. Research Projects must address the research priorities related to the regulatory authority of the Food and Drug Administration (FDA) Center for Tobacco Products (CTP). The awards under this NOFO will be administered by NIH using funds that have been made available through FDA CTP and the Family Smoking Prevention and Tobacco Control Act (P.L. 111-31). Research results from this NOFO are expected to generate findings and data that are directly relevant in informing the FDA's regulation of the manufacture, distribution, and marketing of tobacco products to protect public health.

**Budget:** NIH, via support from the FDA Center for Tobacco Products (CTP), intends to fund up to 6 R01s, corresponding to a total of up to \$4 million, for fiscal year 2024. Future year amounts will depend on the availability of funds. Application budgets are limited to \$500,000 in direct costs per year. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

### 3. Assay Development and Screening for Discovery of Validated Chemical Hits for Brain Disorders (R01 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-23-168](#)

**Type:** R01

**Application Due Date:** June 05, 2023 through to May 07, 2026. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Announcement:** The overarching goal of this Notice of Funding Opportunity (NOFO) is to support the development and validation of screening assays for the discovery of validated hits that can be used in future drug discovery/development efforts for identifying potential drug candidates for the treatment of mental illness. For purposes of this initiative, a "hit" is defined as a compound that has the desired activity in a compound screen and whose activity is confirmed upon retesting in orthogonal assays. Stages of discovery research covered by this NOFO include 1) assay development; 2) primary screen implementation to identify initial screening hits (high throughput target-focused screens, or moderate throughput screens); and 3) hit validation using a series of assays and initial medicinal chemistry inspection to prioritize the hit set.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years

### 4. Innovation for HIV Vaccine Discovery (R01 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-23-169](#)

**Type:** R01

**Application Due Date:** August 02, 2023; August 02, 2024; August 01, 2025. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Announcement:** The purpose of this reissued Notice of Funding Opportunity (NOFO) is to support high-risk, high-impact, early discovery research on vaccine approaches to prevent acquisition of or ongoing infection by HIV. In keeping with the high-risk, high-impact nature of this research, this NOFO supports a Go/No-Go approach to funding high risk research, which is significantly different from most R01 projects. Continued funding for the full award duration is dependent upon achieving negotiated "Go/No-Go" criteria by the end of Year 2.

**Budget:** NIH intends to fund an estimate of 2 to 4 awards, corresponding to a total of \$2M, for fiscal year 2024. Future year amounts will depend on annual appropriations. Application budgets are limited to \$350,000 per year in direct costs. Applicants may request up to an additional \$150,000 per year in direct costs in any year when research in nonhuman primate (NHP) or humanized mice models is proposed and justified. The project period is up to four years. Applicants should submit a 4-year project period and are required to identify Go/No-Go decision criteria to be achieved for the Year 2 progress report to allow continued funding for years 3 and 4. Achievement of the stated goal(s) ("Go") will enable continuation of the R01 for years 3 and 4, while failure to achieve the stated goal(s) ("No-Go") will result in negotiation of a reduced budget for Year 3 and Year 4.

#### 5. Synthetic Nucleic Acid Platforms for HIV-1 (SNAPH): (R61/R33 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-AI-23-026](#)

**Type:** R61/R33

**Application Due Date:** August 02, 2023. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Announcement:** The purpose of this Notice of Funding Opportunity (NOFO) is to advance synthetic nucleic acid platforms for the rapid development and iterative testing of active and passive immunization strategies for HIV prevention, treatment, and cure. This NOFO will use a milestone-driven, biphasic award mechanism. Transition to the second phase will depend on the successful completion of milestones.

**Budget:** NIAID intends to commit \$3,000,000 in FY 2024 to fund 3-5 awards. Application budgets are limited to \$500,000 in direct costs per year in the R61 phase and \$750,000 in direct costs per year in the R33 phase. All F&A costs are excluded from this limit. Requested budgets should reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period for an application submitted in response to this NOFO cannot exceed five years. Applicants may request up to three years of support for the R61 phase, and up to two years of support for the R33 phase.

#### 6. Cancer Prevention, Detection, Diagnosis, and Treatment Technologies for Global Health (U01 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-CA-24-005](#)

**Type:** U01

**Application Due Date:** October 13, 2023. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Announcement:** This Notice of Funding Opportunity (NOFO) supports the development of cancer-relevant technologies suitable for use in low- and middle-income countries (LMICs). Specifically, the NOFO solicits applications for projects to adapt, apply, and validate existing or emerging technologies into a new generation of user-friendly, low-cost technologies for preventing, detecting, diagnosing, and/or treating cancers in people living in LMICs. Applicants should have a working assay or device prototype (not necessarily already capable of cancer applications). The U01 project includes studies to both adapt this technology as well as demonstrate technical functionality and clinical performance for use of the device or assay in specific LMIC settings by meeting objective performance milestones followed by improvements and validations of the technologies in the LMIC settings. Projects proposed in response to this NOFO will require multidisciplinary efforts to succeed; therefore, all applicant teams must include expertise in engineering/assay/treatment development, oncology, global healthcare delivery, and business development. Investigators responding to this NOFO must consider affordability and cost-effectiveness as well as usability at the point-of-need as part of their design criteria. This NOFO is part of a broader NCI-sponsored Affordable Cancer Technologies (ACTs) Program.

**Budget:** NCI intends to commit \$4.0 million to support up to six awards in FY2024. Applicants may request up to \$475,000 in direct costs per year. The proposed project period must not exceed 5 years.

#### 7. Mechanistic Studies to Investigate the Interrelationship Between Sleep and/or Circadian Rhythms and Substance Use Disorders (R01 Clinical Trials Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-DA-24-020](#)

**Type:** R01

**Application Due Date:** November 13, 2023. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Announcement:** The purpose of this Notice of Funding Opportunity (NOFO) is to support research project applications to expand our knowledge on the basic neurobiology of the interrelationship between sleep/circadian rhythms and substance use disorders (SUDs). These mechanistic studies will offer insights into the fundamental processes that link SUDs to disorders of sleep/circadian rhythms and vice-versa, and may also have implications for managing risks associated with developing SUDs and/or identifying new targets for prevention and therapeutics.

**Budget:** NIDA intends to commit \$3M in FY2024 to fund 3-5 awards across this and the companion NOFO, [RFA-DA-24-021](#). Application budgets will be limited to \$300,000 in direct costs/year. The proposed budget needs to reflect the actual needs of the proposed project.

#### 8. Mechanistic Studies to Investigate the Interrelationship Between Sleep and/or Circadian Rhythms and Substance Use Disorders (R01 Basic Experimental Studies with Humans Required)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-DA-24-021](#)

**Type:** R01

**Application Due Date:** November 13, 2023. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Announcement:** The purpose of this Notice of Funding Opportunity (NOFO) is to support basic science experimental studies involving humans to expand our knowledge of the interrelationships between sleep/circadian rhythms and substance use disorders (SUDs). These mechanistic studies will offer insights into the fundamental processes that link SUDs to sleep/circadian rhythms and vice-versa, and may also have implications for managing risks associated with developing SUDs and/or identifying new targets for prevention and therapeutics.

**Budget:** NIDA intends to commit \$3M in FY2024 to fund 3-5 awards across this and the companion NOFO, [RFA-DA-24-020](#). Application budgets will be limited to \$300,000 in direct costs/year. The proposed budget needs to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is five years.

#### 9. Data Integration and Statistical Analysis Methods (DISAM) (U01 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-HG-23-005](#)

**Type:** U01

**Application Due Date:** November 20, 2023. Applications are due by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

**Announcement:** This Notice of Funding Opportunity (NOFO) solicits applications to develop innovative and generalizable statistical and computational methods for analysis of data from the human Developmental Genotype-Expression (dGTEx) and non-human primate (NHP)

dGTE<sub>x</sub>) projects. Methods that assess the influence of genetic variation on development, compare gene expression and regulation across tissues and time points, or leverage comparative genomics to understand developmental and evolutionary processes and integrate with existing tissue and cell atlas efforts are strongly encouraged. This NOFO is open to all applicants regardless of whether they are currently affiliated with dGTE<sub>x</sub>, NHP dGTE<sub>x</sub>, or neither.

**Budget:** Issuing IC and partner [components](#) intend to commit an estimated total of \$2.34M in FY24, \$2.54M in FY25, and \$2.64M in FY26 total cost to fund up to 4 awards. Application budgets allowed up to \$400K direct costs per year, for a project period of 3 years. Budgets are not limited but need to reflect the actual needs of the proposed project. 3 years

Research Development and Support Division (RDSD) &  
Grants Management Office (GMO)  
Faculty of Medicine and Health Sciences  
K<sup>th</sup> Floor, Teaching Block, Tygerberg Campus.  
Enquiries: *Christa*  
e: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) | t: +27 21 938 9838

Division for Research Development (DRD)  
Stellenbosch Campus  
2041 Krottoa Building, Ryneveld Street  
Enquiries: *Lizél*  
e: [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za) | t: +27 21 808 2105